Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials

被引:0
作者
Jiangna Han
Lu Dai
Nanshan Zhong
机构
[1] Chinese Academy of Medical Sciences,Department of Pneumology, Peking Union Medical College Hospital, Peking Union Medical College
[2] Beijing Novartis Pharma Co.,Medical Affairs
[3] Ltd,State Key Laboratory of Respiratory Disease, First Affiliated Hospital
[4] Guangzhou Medical College,Department of Pneumology
[5] Peking Union Medical College Hospital,undefined
来源
BMC Pulmonary Medicine | / 13卷
关键词
Breathlessness; Baseline dyspnea index; Transition dyspnea index; Meta-analysis; COPD;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 181 条
[1]  
Qaseem A(2011)Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society Ann Intern Med 155 179-191
[2]  
Wilt TJ(2010)American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease Chest 137 674-691
[3]  
Weinberger SE(2010)Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone Int J Chron Obstruct Pulmon Dis 5 311-318
[4]  
Hanania NA(2010)Once-daily bronchodilators for chronic obstructive pulmonary disease Am J Respir Crit Care Med 182 155-162
[5]  
Criner G(2010)Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 473-479
[6]  
van der Molen T(2011)Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 273-279
[7]  
Marciniuk DD(2012)Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies COPD 9 1-8
[8]  
Denberg T(2012)Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study Respirology 17 379-389
[9]  
Schünemann H(2011)Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies Clin Ther 33 1974-1984
[10]  
Wedzicha W(2004)Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 932-946